Study of PDR001 and / or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
- 1. Written informed consent must be obtained prior to any screening procedures 2. Male or female patients ≥ 18 years of age who present with one of the following: Arms 1-3: - Refractory/relapsed AML following ≥1 prior therapies and are deemed by the investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established chemotherapy regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded) - De novo AML patients who are suitable for treatment with decitabine (patients who are suitable for standard induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded) - High risk MDS (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded) Arms 4-5: - Refractory / relapsed AML following ≥1 prior therapies (Arms 4a & 5a) - High risk MDS who have failed hypomethylating agent therapy (Arms 4b & 5b) (Note: hypomethylating agent failure is defined as progressive disease on hypomethylating agent therapy or lack of clinically meaningful response as deemed by investigator after at least 4 cycles of hypomethylating agent therapy.) 3. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 4. Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutions guidelines and be willing to undergo a bone marrow aspirate and/biopsy at screening, during and at the end of therapy on this study. Exceptions may be considered after documented discussion with Novartis. 5. Arms 1-3: Patients must be fit for standard treatment with decitabine as determined by the investigator and as per local decitabine package insert.
Trial Phase Phase I
Trial Type Treatment
Novartis Pharmaceuticals Corporation
- Primary ID CPDR001X2105
- Secondary IDs NCI-2017-02439
- Clinicaltrials.gov ID NCT03066648